Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review

Over the past decade, the treatment landscape of chronic lymphocytic leukemia (CLL) has dramatically changed, shifting from cytotoxic chemotherapy to targeted therapies. Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the treatment of CLL and are increasingly applied in many other mali...

Descripción completa

Detalles Bibliográficos
Autores principales: Quartermaine, Cooper, Ghazi, Sanam M., Yasin, Aneeq, Awan, Farrukh T., Fradley, Michael, Wiczer, Tracy, Kalathoor, Sujay, Ferdousi, Mussammat, Krishan, Satyam, Habib, Alma, Shaaban, Adnan, Kola-Kehinde, Onaopepo, Kittai, Adam S., Rogers, Kerry A., Grever, Michael, Ruz, Patrick, Bhat, Seema, Dickerson, Tyler, Byrd, John C., Woyach, Jennifer, Addison, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
State-of-the-Art Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635896/
https://www.ncbi.nlm.nih.gov/pubmed/37969643
http://dx.doi.org/10.1016/j.jaccao.2023.09.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635896/
https://www.ncbi.nlm.nih.gov/pubmed/37969643
http://dx.doi.org/10.1016/j.jaccao.2023.09.002

Ejemplares similares